The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine's safety in older adults, a group at increased risk of severe complications from COVID-19. It tested two doses of Moderna's vaccine - 25 micrograms and 100 micrograms - in 40 adults aged 56 to 70 and 71 and older. One developed a grade three fever, which is classified as 102.2 degrees Fahrenheit (39°C) or above, after receiving the lower vaccine dose. "This is similar to what a lot of older adults are going to experience with the high dose influenza vaccine," Anderson said. Hulme said he was aware Moderna's vaccine employed a new technology, and that there might be a risk in taking it, but said, "somebody had to do it."

Source: bd News24 September 29, 2020 21:00 UTC